SyntheMed Nominated for Frost & Sullivan Award
The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier.
Profiles
CNS Closes $1M Bridge Loan, Completes Clinical Trial Enrollment
The money will allow CNS Response, based in Costa Mesa, Calif., to complete an upcoming depression study.
BioNeutral Ships Mold-Fighting Ogiene-M Formulation
BioNeutral, a life science company that specializes in biohazard neutralization technologies, has started shipping its Ogiene-M formulation to fulfill an agreement between BioNeutral and Mr. Mold.
Clarient Launches New Gene Mutation Test for Lung Cancer
Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
TearLab Wins Silver Medical Design Excellence Award
TearLab Corporation of San Diego announced that its TearLab Osmolarity System has received a Silver 2009 Medical Design Excellence Award.
Correction: Sentinel – Symphony Medical
In last week’s Sentinel, OneMedPlace reported that Symphony Medical had initiated a Phase II clinical trial of their Plexisyl-AF device to treat atrial fibrillation.
HealthTronics to Buy Endocare
HealthTronics announced that it has entered into a definitive merger agreement with Endocare.
Electro-Optical Submits MelaFind for Premarket Approval
Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Sensimed Honored With Red Herring Award
Sensimed, a Swiss company focused on the development of integrated micro-systems for medical devices, has received the Red Herring 100 Europe 2009 Award.
SyntheMed’s REPEL-CV Approved by Australian Regulators
REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.